Closed

Lenti-CD47 CAR (scFv-CD4ζ, B6H12.2)-VP (VP-CAR-LC127)

The ready-to-use lentiviral particles of Lenti-CD47 CAR (scFv-CD4ζ, B6H12.2)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (B6H12.2)-CD4-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Specifications

  • Type of Therapeutics
  • Chimeric Antigen Receptor
  • Target
  • CD47
  • Expression Cassette
  • scFv (B6H12.2)-CD4-CD3ζ
  • Clone
  • B6H12.2
  • Promotor
  • EF1a
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • B-cell malignancies

Target

  • Introduction
  • CD47 (CD47 Molecule) is a Protein Coding gene. Diseases associated with CD47 include Hereditary Spherocytosis and Neonatal Meningitis. Among its related pathways are Response to elevated platelet cytosolic Ca3+ and Innate Immune System. Gene Ontology (GO)nnotations related to this gene include thrombospondin receptor activity.
  • Alternative Names
  • CD47 Molecule; Antigenic Surface Determinant Protein OA3; CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer); Antigen Identified By Monoclonal Antibody 1D8; Leukocyte Surface Antigen CD47; Integrin Associated Protein; Rh-Related Antigen; CD47 Glycoprotein;

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.